Information Provided By:
Fly News Breaks for March 8, 2017
CYTK
Mar 8, 2017 | 07:03 EDT
Rodman & Renshaw analyst Joseph Pantginis started Cytokinetics with a Buy rating and $25 price target. The analyst views the stock as a core long-term holding for investors.
News For CYTK From the Last 2 Days
There are no results for your query CYTK